Current Issue
Volume 1, Issue 1 - 2026 ((April-June 2026) )
Issue Details:
Volume 1 Issue 1 ((April-June 2026))Issue Description:
The April-June 2026 issue invites high-quality submissions highlighting recent advances and innovations in bioengineering and biosciences. We welcome original research, reviews, and short communications across areas such as synthetic biology, biomedical engineering, drug development, and regenerative medicine. All manuscripts will undergo rigorous peer review, ensuring high scientific standards and global visibility. This issue offers an excellent platform to showcase impactful research to the international scientific community. Submit your valuable work and contribute to advancing the field.
Editor-in-Chief
Journal of Development in Bioengineering and Biosciences
Articles in This Issue
ATRIAL FIBRILLATION AND PSYCHOSOCIAL STRESS: Epidemiology, Risk, Mechanisms and Future Directions
Atrial fibrillation (AF), the most common cardiac arrhythmia links to significant morbidity, mortality, and healthcare costs through typical risks like ageing, hypertension, and structural heart disease. Recent studies show chronic psychosocial stress, negative emotions, and mental health factors in AF susceptibility. This review integrates AF epidemiology, focusing on mental stress and adverse emotional states interacts with atrial electrophysiology. Key mechanisms include sympathetic upregulation, parasympathetic attenuation, HPA axis overdrive, inflammation, and myocardial remodelling. Observational data associate persistent stress with higher AF incidence yet causation and stress reduction effectiveness remain uncertain. Targeting modifiable psychosocial factors mat contribute to improve risk stratification management and quality of life.
Contributors:
Preclinical Drug Development: Application Of Advanced Models And Predictive Methods In Safety Assessment
Preclinical drug development faces inherent limitations associated with conventional models, such as two-dimensional cell cultures and animal models, which exhibit limited physiological relevance and contribute to high attrition rates in clinical phases. NAMs, including human organoids, organ-on-chip systems, microphysiological platforms, physiologically based pharmacokinetic modeling, omics technologies, and artificial intelligence, provide an integrated and predictive framework for the assessment of organ-specific toxicities, mechanistic characterization, and human extrapolation. These tools enable dose optimization, improved risk monitoring, and reduction in animal use. Nevertheless, challenges remain regarding functional maturation, experimental reproducibility, regulatory validation, and population representativeness. The strategic and combined application of NAMs constitutes an advanced preclinical ecosystem that complements traditional approaches and holds significant potential to enhance the safety and efficacy of drug candidates in development.